Akoya Biosciences Inc. (AKYA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Akoya Biosciences Inc. (AKYA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.66

-0.27 (-9.22%)

At close: Jan 14, 2025, 3:59 PM

2.53

-4.85%

Pre-market Jan 15, 2025, 08:00 AM EST

undefined% (undefined)

Bid	2.55
Market Cap	131.84M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.16
PE Ratio (ttm)	-2.29
Forward PE	n/a
Analyst	Hold

Ask	2.8
Volume	462,046
Avg. Volume (20D)	573,486
Open	3.01
Previous Close	2.93
Day's Range	2.63 - 3.10
52-Week Range	1.88 - 6.31
Beta	undefined

About AKYA

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze...

[Show more]

Industry Medical - Instruments & Supplies

Sector Healthcare

IPO Date Apr 16, 2021

Employees 330

Stock Exchange NASDAQ

Ticker Symbol AKYA

Website https://www.akoyabio.com

Analyst Forecast

According to 7 analyst ratings, the average rating for AKYA stock is "Hold." The 12-month stock price forecast is $3.5, which is an increase of 31.58% from the latest price.

Buy 42.86%

Hold 57.14%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Akoya Biosciences Inc. is scheduled to release its earnings on Mar 3, 2025, during market hours.
Analysts project revenue of $21.23M, reflecting a -19.85% YoY shrinking and earnings per share of -0.16, making a -27.27% decrease YoY.

Why Price Moved

2 months ago · Source

-23%

Akoya Biosciences shares are trading lower after t... Unlock content with Pro Subscription

2 months ago · Source

-2.49%

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

News

2 days ago · https://thefly.com

Quanterix price target lowered by $4 at TD Cowen, here's why

Quanterix + Akoya Biosciences +0.39 (+14.72%)

4 days ago · businesswire.com

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Bioscience...

5 days ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Akoya (NASDAQ: AKYA) for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix. Click here to learn h...

5 days ago · businesswire.com

AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akoya Biosciences, Inc. (NASDAQ: AKYA) to Quanterix Corporation for 0.318 shares of Quant...

5 days ago · businesswire.com

Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

BILLERICA, Mass. and MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Bioscience...

2 months ago · seekingalpha.com

Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call ...

2 months ago · zacks.com

Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.